AI Article Synopsis

  • The study evaluated the characteristics, treatments, and outcomes of patients who experienced both acute myocardial infarction (AMI) and acute intracranial hemorrhage (ICH), finding that this combination is rare, affecting only 8 out of 4,972 AMI patients (0.2%).
  • Most cases of ICH occurred shortly after an AMI event, primarily resulting in significant drops in consciousness and presenting with irregular hematoma shapes on CT scans.
  • The findings indicated a high mortality rate and poor functional outcomes, with 2 deaths within a week and 2 out of 6 survivors exhibiting significant disability at one year post-event, highlighting the risks associated with these concurrent conditions.

Article Abstract

This study aimed to evaluate the demographic and clinical characteristics, treatments and outcomes of concomitant acute myocardial infarction (AMI) and acute intracranial hemorrhage (ICH). All patients diagnosed with concomitant AMI and acute ICH admitted to our institution were included retrospectively. The patient demographics, clinical characteristics, neuroimaging and treatment approaches were analyzed, and the outcomes of interest included disability as defined by the modified Rankin Scale (mRS) score and all-cause mortality within 1 year of follow-up. Of a total of 4972 patients with AMI, 8 patients (0.2%) with concomitant acute ICH were recruited for the study, including ST-segment elevation myocardial infarction (STEMI, 5 cases) and non-STEMI (3 cases). New-onset acute ICH in 4 of the 5 patients (80%) occurred within 24 hours after the AMI event, and all these patients had a sudden decrease in the level of consciousness, with an average decrease of 4.6 on the Glasgow Coma Scale. All 5 out of 8 patients had irregular shapes and uncommon sites of hematoma presentation documented on CT scans. Unfortunately, 2 patients died from a progression of ICH within 1 week, and 2 of the 6 survivors had poor functional outcomes (mRS ≥3) at the 1-year follow-up. Concomitant acute ICH and AMI are rare complications displaying unique iconography. Acute ICH caused serious prejudice in AMI with higher mortality and poor functional outcomes, and cardiac catheterization without the administration of antithrombotic or antiplatelet agents was feasible for patients who had unstable hemodynamics or STEMI.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726952PMC
http://dx.doi.org/10.1136/jim-2022-002334DOI Listing

Publication Analysis

Top Keywords

acute ich
20
concomitant acute
16
myocardial infarction
12
clinical characteristics
12
acute
9
acute myocardial
8
acute intracranial
8
intracranial hemorrhage
8
ami acute
8
patients
8

Similar Publications

Background: Intracerebral hemorrhage (ICH) is the most severe and disabling stroke, accounting for up to 50% of the cases in low-to-middle-income countries. High rates of cognitive decline and dementia follow acute ICH, due to the common underlying vasculopathy of cerebral small vessel disease (CSVD). The international clinical trial, TRIDENT (Triple therapy prevention of Recurrent Intracerebral Disease EveNts Trial), aims to determine the effectiveness of the fixed low-dose Triple Pill combination of blood pressure-lowering agents (telmisartan 20 mg, indapamide 1.

View Article and Find Full Text PDF

Therapeutic hypothermia in preterm infants under 36 weeks: Case series on outcomes and brain MRI findings.

Eur J Pediatr

January 2025

Neonatology Department. Hospital Sant Joan de Déu, Center for Maternal Fetal and Neonatal Medicine. Neonatal Brain Group, Universitat de Barcelona. Hospital Clínic, Universitat de Barcelona. BCNatal - Barcelona, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.

Purpose: Perinatal hypoxic-ischemic encephalopathy (HIE) is a significant cause of neonatal brain injury. Therapeutic hypothermia (TH) is the standard treatment for term neonates, but its safety and efficacy in neonates < 36 weeks gestational age (GA) remains unclear. This case series aimed to evaluate the outcomes of preterm infants with HIE treated with TH.

View Article and Find Full Text PDF

Purpose: Tirofiban has emerged as an adjunct therapy for acute ischemic stroke (AIS) patients undergoing endovascular treatment (EVT). However, its benefits for AIS patients with intracranial atherosclerotic disease (ICAD) remains unclear. This meta-analysis evaluates its efficacy and safety in ICAD-related AIS patients undergoing EVT.

View Article and Find Full Text PDF

Intracerebral hemorrhage (ICH) presents complex clinical challenges, particularly in patients receiving anticoagulation therapy. This case report discusses the management of acute ICH in a 60-year-old male patient on long-term apixaban therapy, who arrived at the emergency department with altered consciousness, right-sided hemiplegia, and mixed aphasia. Computed tomography (CT) imaging revealed a 70 ml left lenticular-capsular hematoma with significant mass effect, necessitating rapid intervention.

View Article and Find Full Text PDF

Antiplatelets before or during endovascular therapy after intravenous thrombolysis for atherothrombotic large vessel occlusion.

J Clin Neurosci

December 2024

Department of Stroke and Cerebrovascular Diseases, University of Tsukuba Hospital, Tsukuba, Japan; Department of Neurosurgery, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.

Article Synopsis
  • Re-occlusion and thrombus formation after mechanical thrombectomy in stroke patients can lead to worse outcomes, but early antiplatelet therapy (APT) may help prevent these issues.
  • Current guidelines recommend waiting to use APT after intravenous thrombolysis, which complicates treatment for large vessel occlusion strokes.
  • A study of 164 patients in Japan suggests that starting APT early post-thrombolysis is safe, with no significant differences in hemorrhagic events or mortality compared to those who started APT later or not at all.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!